Low-dose Neostigmine at TOF Ratio of 0.7 Improves Neuromuscular Recovery

Low-dose Neostigmine at TOF Ratio of 0.7 Accelerates Neuromuscular Recovery Without Adverse Effects: a Prospective Observational Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06745492

Enrollment

Registered

2024-12-20

Start date

2022-10-01

Completion date

2023-08-25

Last updated

2024-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recovery Time

Brief summary

This study is a prospective observational study. A total of 54 patients were included in this study. We observed the time from neostigmine administration to TOF ratio of 1.0.

Interventions

DRUGNeostigmine + Glycopyrrolate

a 20 mcg/kg of neostigmine and 4 mcg/kg of glycopyrrolate were administered at a TOF ratio of 0.7.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients undergoing elective thyroid surgery under general anesthesia * a body mass index of 18.5-25 kg/m2 * Age ≥ 20

Exclusion criteria

* Refused to participate * history of hypersensitivity to acetylcholinesterase inhibitor * neuromuscular disease * hepatic or renal dysfunction

Design outcomes

Primary

Measure	Time frame	Description
Recovery time	During surgery	Time from neostigmine administration to TOF ratio of 1.0

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026